BSE · 524314
Gujarat Terce Laboratories Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹11 Cr with net profit ₹0 Cr — a 0.88% net margin, versus 6.18% the period before.
Shareholding
As of 2026-06-30
- Promoter40.03%
- Public59.97%
13,755 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.06× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #35 of 50 by market cap · medians across 41 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,86,243 Cr | 84.98 | 22.15 | 25.49% | 15.55% |
| Ajanta Pharma Limited | ₹42,303 Cr | 158.59 | 9.38 | 23.33% | 19.37% |
| Gland Pharma Limited | ₹41,329 Cr | 112.55 | 3.99 | 9.92% | 15.98% |
| Rubicon Research Limited | ₹25,106 Cr | 325.62 | 19.52 | 19.14% | 14.07% |
| Caplin Point Laboratories Ltd. | ₹19,786 Cr | 116.31 | 5.52 | 17.88% | 29.32% |
| Eris Lifesciences Limited | ₹19,528 Cr | 68.41 | 5 | 15.87% | 19.89% |
| Marksans Pharma Limited | ₹11,778 Cr | 79.48 | 3.9 | 13.82% | 14.16% |
| Shilpa Medicare Ltd. | ₹11,745 Cr | 108.98 | 4.53 | 9.39% | 15.81% |
| Senores Pharmaceuticals Limited | ₹6,127 Cr | 167.12 | 6.56 | 12.36% | 18.32% |
| Bliss GVS Pharma Ltd. | ₹4,853 Cr | 142.1 | 4.06 | 8.95% | 11.15% |
| Gujarat Terce Laboratories Ltd.(this company) | ₹29 Cr | 11.7 | 3 | 25.62% | 4.68% |
AI analysis
AI-generated · google/gemini-2.5-flashGujarat Terce Laboratories Ltd. is listed on the Indian markets with a market capitalization of Rs 26 Cr. The company reported revenue of Rs 50.5 Cr and an EPS of Rs 3.2. Its trailing twelve months profit margin stands at 467.7%.
Positives
- +The trailing twelve months profit margin of 467.7% is high.
- +The debt-to-equity ratio of 0.35 is low.
- +The Return on Equity (ROE) of 25.62% is high.
- +The Return on Capital Employed (ROCE) of 29.2865% is high.
Negatives
- −Net profit for the fiscal year ending March 2025 was negative at -Rs 0.9787 Cr.
- −Net profit for the quarter ending June 2025 was negative at -Rs 0.04 Cr.
- −Promoter shareholding has steadily declined from an unspecified percentage in March 2016 to 40.0278% in June 2026.
- −No quarterly results have been disclosed since March 2026.
- −No revenue growth figure was provided in the data.
Financial performance
The company's revenue for the fiscal year ending March 2025 was Rs 50.503 Cr. Over the last three reported quarters in fiscal year 2026, revenue was Rs 10.85 Cr in June 2025, Rs 12.93 Cr in September 2025, and Rs 12.29 Cr in December 2025. The net profit was -Rs 0.9787 Cr for the year ending March 2025, and -Rs 0.04 Cr, Rs 1.4 Cr, and Rs 0.76 Cr for the June, September, and December 2025 quarters respectively.
Profitability & Returns
Gujarat Terce Laboratories Ltd. registered an EPS of Rs 3.2. The company's Return on Equity (ROE) is 25.62% and Return on Capital Employed (ROCE) is 29.2865%. The profit margin for the trailing twelve months is 467.7%.
Balance Sheet
The company maintains a book value of Rs 12.49. The debt-to-equity ratio is 0.35, indicating a relatively low level of debt compared to equity.
Ownership & Pledges
Public shareholding stands at 59.9722%. There were no promoter pledges reported for the period ending June 2026.
Data as of — price: 2026-07-29 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Gujarat Terce Laboratories Ltd.share price & fundamentals